A. Selective inhibition of the antiapoptotic protein BCL2 B. Disruption of the B-cell receptor signaling pathway by inhibition of phosphatidylinositol-3-kinase C. Bruton's tyrosine kinase inhibitor D. PD-1–blocking antibody

A. Idelalisib alone B. Idelalisib and rituximab C. Fludarabine, obinutuzumab, and chlorambucil D. Chlorambucil and prednisone

A. Hepatic failure B. Tumor lysis syndrome C. Stroke D. Hypersensitivity reactions

A. Chlorambucil and prednisone B. Bendamustine and rituximab C. Ibrutinib alone D. Idelalisib and obinutuzumab

A. Venetoclax B. Obinutuzumab plus chlorambucil C. Idelalisib D. Idelalisib and rituximab

A. Ofatumumab is associated with a warning regarding hepatitis B virus (HBV) reactivation; rituximab and obinutuzumab are associated with a warning regarding the development of progressive multifocal leukoencephalopathy (PML). B. Only rituximab, but no other CD20-targeting agent, is associated with a warning regarding HBV reactivation and the development of PML. C. All CD20-targeting agents are associated with a warning regarding HBV reactivation and development of PML. D. All CD20-targeting agents are associated with a warning regarding HBV reactivation but not the development of PML.

A. Ibrutinib is recommended only after prior treatment with fludarabine, cyclophosphamide, and rituximab. B. Guidelines from the National Comprehensive Cancer Network recommend the use of ibrutinib as a first-line agent for newly diagnosed CLL in patients harboring the 17p deletion. C. Ibrutinib is US Food and Drug Administration-approved for first-line treatment of patients with CLL in combination with rituximab. D. Ibrutinib should not be used in relapsed/refractory CLL patients.

A. Myocarditis B. Seizure and arrhythmias C. Pneumonia, neutropenic fever, and diarrhea D. Nausea, vomiting, peripheral neuropathy

A. Ibrutinib may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies, and as a result monitoring for signs of bleeding is required. B. Ibrutinib does not have any significant drug-drug interactions and special monitoring parameters are not necessary. C. The most common adverse effects of any grade seen the RESONANTE-2 trial for ibrutinib were vomiting, hemolytic anemia, and syncope. D. Treatment with ibrutinib does not require monitoring of complete blood counts due to minimal effects on blood cells.